Artificial intelligence (AI) continues to revolutionise healthcare, and dermatology is evolving with it. Recent data values the AI-powered drug discovery market in dermatology at USD 234.7 million in 2024. Experts project it will grow to USD 1,924.6 million by 2034, fuelled by a strong CAGR of 24.2 per cent from 2025 to 2034.
Transforming dermatology with AI
AI-driven drug discovery uses machine learning, deep learning, and natural language processing to speed up the development of treatments for skin conditions. It helps create therapies for psoriasis, atopic dermatitis, acne, vitiligo, and skin cancer more efficiently. AI systems analyse biological data to identify drug targets, predict efficacy, and repurpose existing medications for skin conditions.
AI enhances dermatology by detecting and categorising skin conditions through imaging with accuracy matching or surpassing human expertise. These capabilities are dramatically improving diagnosis speed, accuracy, and treatment outcomes.
Market segmentation and growth drivers
Researchers segment the market by AI models, drug types, medical indications, and end-users to analyse growth and adoption trends. Notably, small molecules are expected to dominate due to their high commercial viability and targeted therapeutic potential.
Pharmaceutical companies lead market adoption by leveraging their R&D capabilities, investing in AI platforms, and applying their regulatory expertise. They increasingly use AI to shorten time-to-market, cut development costs, and enhance treatment precision.
North America leads, Asia-Pacific rising
Advanced healthcare infrastructure, high R&D investment, and rising skin condition cases help North America hold the largest market share. Meanwhile, Asia-Pacific rapidly emerges, fuelled by tech adoption, demand for faster diagnoses, and a growing patient base.
Strategic collaborations fuel innovation
A key highlight includes the February 2024 partnership between Microsoft and Almirall to build an AI-powered drug discovery platform tailored for dermatology. Microsoft and Almirall combine AI and dermatology expertise to streamline drug development and accelerate next-generation treatment delivery.
AI-powered drug discovery is reshaping the dermatology landscape. Growing adoption and collaboration drive the sector toward a multi-billion-dollar market, delivering faster, accurate, and personalised care globally.